Infectious Diseases Blog

Viruses and Cancer: What’s the Link?

-Blogger's note: This entry was penned by pharmacy students Gerard P. Mascara & Eric E. Gardner, of the Rho Chi Society, Alpha Omicron chapter, and represents the inaugural Rho Chi ID blog contribution which will appear monthly.

Today, Gardasil® (Quadrivalent human papilloma virus recombinant vaccine) is routinely administered to young women to prevent infection from human papilloma virus (HPV).Pitt pharmacy students fortunate enough to see Dr. Schiff’s vivid photos of acute infection with HPV may feel that prevention of these disfiguring genital warts be reason enough to initiate a widespread vaccination campaign against the virus.Yet we know the vaccine’s true indication is to prevent the leading cause of cervical cancer. . . but what on earth do viruses have to do with cancer?

History as teacher

At the University of Pittsburgh School of Pharmacy, one of the major historical links between viruses and cancer hits very close to home (yes, we sometimes do feel as if we live in Salk hall).The Salk inactivated polio vaccine, which was hugely successful in preventing polio, was found to be contaminated with Simian Virus 40 (SV40) several years after it had already been administered to millions of Americans.The further observation that SV40, a “monkey virus” which infected the rhesus kidney cells in which the vaccine was produced, caused transformation of several nonhuman cell lines into cancerous cells caused great alarm and led to intense study of the link between cancer and the virus, and the possible ramifications of exposure.While the jury is still out (and most likely is out for good[1]) on whether or not this contamination led to an increased rate of cancer in exposed individuals, scientists’ intense scrutiny of the virus contributed to the discovery of one of the archetypical tumor suppressors, the retinoblastoma (Rb) protein. The SV40 viral protein dubbed “large T antigen” inactivates Rb, thereby mitigating its critical role in cell cycle regulation.Loss of Rb-mediated cell cycle control can lead to enhanced proliferation and, when combined with additional cumulative genetic or epigenetic changes, can lead to overt cancer.While issues of infectivity and transmissibility may hamper SV40’s contribution to the development of human cancers, the role of HPV in causing human cervical cancer has been established with much more certainty.Interestingly, HPV also encodes a viral protein named E7 which inactivates the Rb tumor suppressor and gives infected cells a growth advantage, ultimately leading to cervical cancer in a fraction of infected individuals. Thus, while a vaccine to “prevent all cancers,” may be unrealistic at this point in time, when we consider the multitude of ways cancers emerge in the human body, it can be appreciated that we have been able to develop several vaccines against specific, known etiologic agents.

For discussion

A detailed counseling session on the importance of mitigation of Rb tumor suppressor function in the biology of cervical cancer would not be an effective way to convince a teenage girl to receive the vaccine; however, we do feel that an appreciation of some key historical events leading to the discovery of the Rb tumor suppressor and the molecular link between HPV and cervical cancer is valuable information for all pharmacists.Other than discussing molecular biology, what strategies would you, as a pharmacist, employ to convince women to receive the HPV vaccine?

On another note, contamination of the polio vaccine led to a great deal of negative press about the safety of vaccinations.In more recent times, worries about safety ranging from autism to Guillain-Barré Syndrome have caused patients and their caregivers to refuse vaccination.How would you try to convince these patients that the benefits of vaccination outweigh the potential risks?

[1] Fisher SG, Weber L, Carbone M. Cancer risk associated with simian virus 40 contaminated polio vaccine. Anticancer Res. 1999;19(3B):2173-80.

0 comments

Take a Breath: Slow Down to Prevent Medication Errors during Flu Season!

-Blogger's note: This entry was penned by medication safety expert Robert J. Weber, RPh, MS, Executive Director of Pharmacy, UPMC Presbyterian Hospital.

The Reality:

The situation of anxious patients wanting to get immunized is a risk for making a mistake in preventing or treating influenza.Long lines of patients will cause immunizers to hurry; vaccine-naïve patients will not want to wait in offices, clinics and pharmacies to be monitored for side effects; both injections of influenza vaccine will be packaged in a vial, and there is a manufacturer’s shortage of oseltamivir suspension.

Pharmacist immunizations.jpg
Here are 7 steps to prevent vaccination errors:

1.) Get H1N1 influenza vaccine from an authorized source

  • H1N1 influenza vaccine may only be acquired from the federal government through your state’s department of health.

2.) Take a deep breath and concentrate

  • Immunization clinics will be crowded, and every patient is different – anatomy, attitude towards shots, etc.Have a “plan” for each patient you vaccinate – site, monitoring, etc.

3.) Check for vaccine indications/contraindications

  • Check patients for previous vaccine reactions and egg allergy;

4.) Choose the right vaccine

  • As the seasonal influenza and H1N1 vaccines may be in vials, make sure you choose the right vaccine for your patient;
  • Avoid mix-ups in refrigerators by storing vaccines in separate and clearly-marked bins;

5.) Be careful with needle sticks

  • Remember - Inject, pause, activate safety device, discard syringe, place band-aid on patient’s arm.Preventing a needle stick by slowing down will alleviate much hassle in the long run!

6.) Label the vaccine for administration

  • This prevents mix-ups in situations where multiple vaccines are prepared “in bulk” for clinics

7.) Monitor vaccine-naïve patients carefully

  • People may be in a rush to get the vaccine and get home or back to work – make sure that first time patients receiving vaccine wait at least 10 minutes to determine an immediate reaction
  • Serious reactions to vaccines are VERY rare, but can occur and are almost Type I hypersensitivity reactions, requiring intramuscular epinephrine

Additionally: Order a patient’s dose of oseltamivir suspension in milligram doses ONLY

  • The commercially available TAMIFLU® is manufactured in a 12 mg/mL suspension (oseltamivir base).Pharmacists have begun to compound the product, on an emergency basis, according to FDA-approved directions listed in the product labeling. The suspension is made from powder in Tamiflu capsules, and results in a 15 mg/mL oseltamvir base concentration, not the 12 mg/mL base concentration which is available commercially.
  • There will be a 25% overdose of oseltamivir if ordered using the standard “ml” dose.Side effects of oseltamivir include GI upset, abdominal pain, nausea/vomiting and abnormal behavior.

Help spread the word:

If we follow these fundamental rules, and remind our colleagues to do the same, our patients will receive vaccine safely and prevent any unnecessary stress for immunizers during this year’s influenza season.

And you can breathe easier.

1 comment

Man vs. Microbe: What is the Best Strategy in the War Against Resistance?

-Blogger's note: This entry was penned by PharmD candidate Stephanie Shuey while completing the Infectious Diseases APPE rotation at UPMC Presbyterian.

The Problem

Antibiotic resistance represents one of the biggest challenges clinicians face every day in the treatment of infectious diseases.From a pharmacy perspective, we know that this issue heavily impacts the way we manage drug therapy.Institution-specific antibiograms are used to guide therapy, empiric coverage is narrowed as quickly as possible, formularies are designed to restrict overuse of broad spectrum antibiotics, and so on. Despite such efforts, the increasing prevalence of organisms such as MRSA and VRE suggest that in the war against resistance, we’re losing a lot of good antibiotics to the microbes.In fact, a recent report from the London School of Economics and Political Science (LSE) highlights research that suggests penicillin is becoming obsolete, particularly in developing countries and areas of Europe where prescribing patterns and over-the-counter availability of antibiotics contribute to heightened resistance.This is a scary finding and it points to a need for new battle tactics.Over the course of the past few months, two interesting strategies have received some attention in the media.

What’s new?

In the LSE report, Elias Mossialos and colleagues propose that increasing microbial resistance is due, in part, to a lack of new antibiotics.The authors explain that pharmaceutical companies are reluctant to invest in the research and development of antibiotics because they are relatively unprofitable. Drug sales are limited both by the short duration of antibiotic regimens and by the fact that new antibiotics are usually reserved for “last line” use in patients that cannot be treated with first line options, many of which are now generic. Consequently, the authors state that governments should provide pharmaceutical companies with financial incentives to invest in antibiotic development.The report describes several methods for providing these incentives, but the take home message is that it is difficult to develop an approach that distributes the financial risks in a way that both the funder (i.e., the government) and drug developers (i.e., drug companies) benefit.But the more important issue to consider is whether developing new antibiotics will actually solve the underlying problem.It can be argued that organisms will just continue to develop new resistance mechanisms, leaving us in a never-ending race to create novel drugs faster than microbes can evolve.

Fighting Back

The “Preservation of Antibiotics for Medical Treatment Act of 2009” represents a more proactive approach to combating resistance.The intent of this bill is to put an end to the non-therapeutic use of antibiotics in agricultural animals.About 70% of antibiotics and other antimicrobials sold in the U.S. are fed to healthy farm animals in their food and water to prevent infection and/or encourage growth.Studies have shown that this practice contributes to the development of antibiotic-resistant infections in humans, with connections being made to MRSA and certain food-borne illnesses.If passed, this bill will ban the non-therapeutic use of seven classes of antibiotics in livestock while allowing for appropriate therapeutic uses.Unfortunately, opposition from farming organizations such as the National Pork Producers Council is delaying passage of the bill.

Your thoughts?

So what is the best way to slow the progression of antimicrobial resistance?It’s hard to say, but likely a variety of different interventions will be needed to address this ever-growing problem.Is it new antibiotics? Maybe stricter legislation? What about educational programs for patients and prescribers regarding appropriate antimicrobial use? How about guidelines?

Take this opportunity to comment on what you feel the best approach is – what do you think works, and what doesn’t?


1 comment

Exercise: Flexing the Immune System

-Blogger's note: This entry was penned by PharmD candidate Justin Montgomery while completing the Infectious Diseases APPE rotation at UPMC Presbyterian.

There’s good news for those of us who like to hit the gym or go for a run on a regular basis. According to a recent study by Kohut et. al published in the Journal of Infectious Diseases, repeated moderate exercise shows an increased benefit over acute exercise when it comes to reducing some common symptoms associated with influenza infections. In this study, mice were used to model the protective effect of exercise on both the induction and severity of symptoms of a course of influenza infection. Mice were randomized to either a no exercise control group, a chronic exercise group consisting of mice that exercised 5 days a week for 14 weeks at moderate intensity, and an acute exercise group consisting of mice that ran for 45 minutes on a treadmill only on the day of infection. The chronic exercise group was infected intranasally with influenza virus 24 hours after completing their last exercise session and the acute exercise group was infected intranasally 15 minutes after finishing on the treadmill. The mice were then euthanized and examined at either 2, 5 or 10 days.

Curious Results:

At two days post-infection, the chronic exercisers had a lower (but not statistically significant) average viral titer than the control and acute exercise groups. At 5 days post infection, both the chronic and acute exercise groups demonstrated a significantly lower viral titer than the control group. At 10 days all groups showed minimal viral titers. Inflammatory factors in the lungs such as IL-6, TNF-α, MCP-1, MIP-1β, KC, and RANTES were also reduced in both the acute and chronic exerciser groups at day 2 but this effect faded in the acute exercise group and persisted in the chronic exercise group.The researchers also found that the chronic exercisers group experienced the most pronounced reduction of symptoms from the influenza infection, specifically, a reduction in loss of appetite and a reduction in weight loss.

Why the link?

To date, the role exercise plays in various immune responses has not been well understood. This was the first research paper to link moderate exercise before infection to an anti-inflammatory effect at a local site of infection. In 2006, Lowder et al. demonstrated that moderate exercise early after influenza infection leads to a decrease in inflammation at the site of infection. Furthermore, Kohut et. al have previously implicated moderate exercise in increasing antigen-specific IFN-γ, a cytokine important to adaptive and innate immunity against viruses and intracellular bacterial infections, and interleukin 2, an important immune system signaling cytokine. Traditionally, inflammation helps to enhance the immune response and promote healing at the infection site by localizing infecting organisms and allowing for increased fluids, platelets and leukocytes to reach the area. Perhaps exercise provides a way to better balance symptoms of infection with the side effects of immune response such as pain, inflammation and fever.

In Summary

In general, the current body of literature addressing the effects of exercise on the immune system seems to suggest that moderate exercise reduces the severity of infections. In contrast, however, exhaustive exercise has been shown to lead to increased severity of infections. This begs the question – “What is the ideal number of Herculian one-ton sternum presses (see pic) in order to enhance my immune response this flu season?”


0 comments

Image at the Dawn of the Antibiotic Era

Gonorrhea - The Great Crippler - Sterlizer (per photo)

The date this picture was taken is unknown, but likely 1942 or sometime soon after using the statement afixed to the top of the trash can as a clue. If you look closely at the bottom, you'll notice the word "FREE" in caps and bold . . . . very curious.

1 comment

Influenza Transmission: How Close is Too Close?

Last week, a P4 student on rotation was visibly scared when I suggested she don an N95 mask and join the medical team interviewing a patient who was likely to have Tuberculosis (N95 masks filter out infectious respiratory secretions). It occurred to me that many may not appreciate the distance limitations of infectious droplets (infectious respiratory aerosols).

Why Distance is Important

For tuberculosis and influenza, there is no known distance threshold from an infected person that significantly increases your risk. However, it is generally accepted that the closer your contact with an infected person, the greater your risk of acquiring disease. You might think to yourself, "Everyone knows that you should keep a distance from acquaintances that appear ill, this isn't anything new". That's correct - but consider the following in the context of a viral pandemic: Patients with Influenza are infectious 24 hours or more before displaying symptoms. That's worth writing twice. Patients with Influenza are infectious 24 hours or more before displaying symptoms.

Greeting Transmission Risk

This is particularly relevant in a society that typically expresses some kind of physical or close contact when greeting others. The New York Times picked up on this and developed an estimated risk level of contacting Influenza based on how we greet others (presented in a very lighthearted and not completely scientific way).

04greetill.jpgIn summary, in the context of a viral pandemic, it's probably best to avoid the "Bro-Hug" or other close greetings. I suggest sticking with the fist bump (the elbow rub seems awkward and may challenge uncoordinated individuals!!).



2 comments

University of Pittsburgh's H1N1 Portal

Information you need to review:

As you return for the start of another school year, please take the time to familiarize yourself with the University's portal regarding the 2009 H1N1 influenza. www.pitt.edu/swine-flu/. This is a great starting point for keeping up with the latest H1N1 pandemic news, and has links to relevant web sites including the Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services, and the World Health Organization. Additional information includes updates regarding government responses on a state and local level, as well as PITT and UPMC resources through links to the UPMC Center for Biosecurity.

Why?

You will be an important health-care resource to your friends, family, and your patients. This includes educating others how to avoid spreading/contracting the disease, dispelling disease myths, and providing important information about chemoprophylaxis and treatment.

Best wishes for another safe and productive school year!

~Dr. Potoski

Wash your hands with soap and clean running water. Visit www.cdc.gov/h1n1 for more information.
Cover your nose with a tissue when sneezing or coughing. Visit www.cdc.gov/h1n1 for more information.

2 comments

2009 Swine-Origin H1N1 Influenza Vaccine

Do you have questions regarding the forthcoming H1N1 vaccine? USA Today has a succinct Q and A approach with important details, located here: http://www.usatoday.com/news/health/2009-08-23-swine-flu-qna_N.htm?loc=interstitialskip

0 comments

The Swine Flu Game

Did you ever wake up one morning and think to yourself:

"I can handle an influenza pandemic, no problem"?

Me too! So here's your chance to prove it. Check out this web based simulation game that puts you in control of fighting various viral pandemics. You've got a budget, various weapons in your infection control arsenal, and the world. Your job is to deploy your infection control measures to limit viral transmission and death within and across continents.

Have you ever seen the movie WarGames circa 1983 starring Matthew Broderick (three years prior to starring in the '80's classic Ferris Bueller's Day Off)? The one where he challenges a computer program to Global Thermonuclear War, but the stakes are (almost) real? This game is in that vein. Try it out! www.thegreatflu.com


0 comments

Bacterial Resistance Outweighs Influenza Threat

It is true that the 2009 H1N1 influenza virus has received much media attention and even greater attention by the government and local and national healthcare groups. However, the background threat (and arguably the greater of the two) has always been bacterial resistance. Below is an excellent opinion piece published recently in the Wall Street Journal regarding this topic. Enjoy!
http://online.wsj.com/article_email/SB10001424052970204251404574342920287470660-lMyQjAxMDA5MDEwMTExNDEyWj.html#articleTabs%3Darticle


0 comments

Salmonella Outbreak


FDA Salmonella Typhimurium Outbreak 2009. Flash Player 9 is required.

0 comments

Poll Results: Perceptions of Cheap Generic Programs

You’ve been inundated these last several months with polls regarding Senators Obama and McCain, their running mates, simulations of blue and red state electoral college voting, and many a pundit’s spin on what it all means. In an election year with seemingly more coverage than ever, and on the day of the presidential election, why not have a look at the results of one more poll?

I’ve pasted the results of the poll regarding cheap generic antibiotics offered at many chain community pharmacies below. I’m happy to say that there were 74 respondents, approximately 96% of which were pharmacy students (Question 1). Over 90% of respondents work in a “traditional” setting, either a community or hospital pharmacy (Question 2), while approximately 4 out of 5 work in a community pharmacy setting. Of all respondents, the vast majority (approximately 95%) were aware of the “cheap generics” program offered by many community pharmacies (Question 3).



clip_image002.gif

For data interpretation, I’ll play the role of pundit. Within Question 4 below, your agreement was asked regarding five specific statements. The responses could be Strongly Disagree; Disagree, Neither Agree nor Disagree; Agree; or Strongly Agree. Each answer was weighted from 1 to 5 respectively. Unfortunately, the data could not be filtered by pharmacy related job. Some notable observations:

  • Due to an initial error in data collection, the responses for each statement don’t quite total 74. Keep this in mind when interpreting the data.
  • The majority of respondents generally answered in agreement with all statements. Ambivalence was greatest for the statement regarding cheap generic medications spurring patients to ask prescribers for additional refills on their antibiotic prescriptions.
  • Of interest, respondents were in greater agreement that cheap generic antibiotics as a 30 days supply would increase inappropriate antibiotic use more than a 90 days supply would. My interpretation of this finding is that an indication for a 90 days supply of an antibiotic is more uncommon than a 30 day, and for this reason may be more difficult to convince/ask your prescriber for. Essentially, a limited scenario.

clip_image3.gif

As political pundits would tell you, polls (data in general) can be spun in many ways. Before we take our perceptions as fact, consider what one of your colleagues stated in an e-mail to me regarding the “cheap generics” program:

The cheap generics program was created by “. . . a community pharmacist who noticed many of his customers were moving to mail order. He felt this was a bad idea as it led to decreased patient contact so he began to offer his cheap generics . . . .” These programs “. . . save people money and keep mail order from monopolizing the pharmacy
business”. Well said. We know that pharmacists through patient interaction and participation in patient care can improve patient outcome and lead to the safe and effective use of medications. In that respect, no spin is necessary.

0 comments

Chain Pharmacies and Deeply Discounted Generic Medications

Many of you have likely seen advertisements on television or billboards regarding cheap prescription generic medications offered by certain chain pharmacies. One such chain, Giant Eagle Pharmacy, is offering $4 generics for a 30 days supply or $10 for a 90 days supply. This cheap generic medication bonanza was initially begun some time ago by Wal-Mart pharmacy. As time went on other chain pharmacies followed suit or, as the Wall Street Journal deemed in its report in June of this year, joined the "cheap generics bandwagon".
Of course in times of economic stress, this is a blessing. You can get all kinds of generic medications for very inexpensive prices. Further, it's simple. In some cases, all you need to do is visit the website of the chain store in question to peruse the lists of generics by type, name, or brand (I'll include the Giant Eagle website as an example: http://www.gianteagle.com/Main/PharmacyDrugProgram.aspx?cntid=182262). Examples of discounted generic therapies include diabetic medications, cholesterol drugs, drugs for thyroid conditions, and even antibiotics.
Antibiotics?! Cheap generic antibiotics? 30 and 90 days supply of antibiotics? Really?
I'll write no further, but I will ask for 1 minute of your time. I've created a brief survey as I'm interested in your feedback regarding cheap one and three month supplies of antibiotics. The survey is only four questions long and can be accessed by clicking on the hyperlink below. All survery responses are anonymous, but the results will be collected and posted in an upcoming blog. Thanks in advance for taking the survey!

2 comments

Penicillin – What is Old is New Again

This past Sunday, September 28, 2008, marked an important date in the history of mankind. It was the 80th anniversary of Sir Alexander Fleming’s discovery of penicillin. Specifically, Sir Fleming noticed that a mold contaminating a plate of Staphylococci in his laboratory had produced a zone of Staphylococcal growth inhibition. His conclusion: The contaminating mold (Penicillum notatum) was producing an unknown substance that was responsible for the inhibition of Staphylococcal growth. The antibiotic era had begun.

Much has transpired since the 1920’s. In the context of this blog, I’m referring to bacterial resistance. Bacteria intent on survival are keen to acquire or create new mechanisms of resistance due to antibiotic pressure. Over time, penicillin has fallen victim to these resistance mechanisms, which are now widespread in many Gram-positive organisms, particularly Staphylococci. For example, of the 2,054 non-duplicate isolates of Staphylococcus aureus tested for penicillin susceptibility at UPMC Presbyterian in 2007, only 9% were susceptible. This is a far cry from Sir Fleming’s time when resistance was likely to be less than 1%. As a result, penicillin is rarely used empirically, and in only limited situations used as directed therapy.

PCN2.PNG

Sidebar: Resistance to penicillin in many Streptococcal species has not been so easy. Why is that? In short, expressing bacterial resistance mechanisms is at a cost to a bacteria’s own fitness. The parallel in our lives would be: Who is likely to live longer? The man/woman who works an 80 hour/week job, or the one who works the same job but works 40 hours/week? In some bacterial species the cost is greater than others (more on bacterial fitness in future blogs).

Refocus: Why is this important? Consider the following. The most common cause of community acquired pneumonia (CAP) is Streptococcus pneumoniae. Previously if a S. pneumoniae causing pneumonia in a patient was tested by a clinical microbiology lab and found to have a minimum inhibitory concentration of >= 0.12mcg/ml, that was interpreted as resistant. In other words, if penicillin was used to treat this patient, the likelihood of a good clinical outcome was low. Over time, it has been shown in several clinical studies, that this breakpoint concentration for resistance was too conservative, and recently a resistance breakpoint of >= 8mcg/ml was endorsed as appropriate for S. pneumoniae non-meningitis disease. In doing so the resistance rate for penicillin in S. pneumoniae fell dramatically. For example, in 2007 at UPMC Presbyterian, resistance fell from 25% to 2%.

How will practice change as a result? The Current guidelines for CAP don’t include penicillin as an empiric therapy option, as these breakpoints were changed after the publication of the most recent CAP guidelines. In future guidelines, penicillin (plus an additional agent for Hemophilus influenzae and atypical organisms) will be the new recommended empiric therapy in patients with CAP. What is old is new again indeed.

0 comments

Influenza Vaccine: Benefiting Mother and Baby

The Background:

The current CDC immunization guidelines for adults state that annual influenza vaccinations are recommended for patients aged 50 years of age and older. For those less than 50, the vaccine is not routinely recommended unless certain medical, occupational, or other conditions exist. One of these medical conditions is pregnancy during the influenza season (roughly October through February or March).

This recommendation stems from the risk of severe consequences related to influenza infection in the pregnant mother. The influenza vaccine, which is inactivated, is safe for the fetus but it is previously unknown whether any benefits are accrued in the neonate once the mother gives birth (remember, neonatal immunity is passive immunity from the mother). Why don’t we just administer the vaccine to infants less than 6 months of age? The vaccine is not licensed for those that young because there are no data.


What’s New?

A recent study published in the New England Journal of Medicine details a prospective study where pregnant mothers received either the influenza vaccine or control. Mothers and babies were assessed by investigators over a 17 month period. The complete results can be found here http://content.nejm.org/cgi/content/full/NEJMoa0708630?query=TOC

In summary, the results indicated a 63% reduction in proven influenza illness in babies (up to 6 months of age) of mothers that received the influenza vaccine while pregnant versus the control group. Additionally, secondary outcomes were favorable in this arm as well (including clinic visits, any respiratory illness with fever, etc.).

How can we improve the lives of our patients with this knowledge?

For pharmacists in all health-care settings, we can encourage pregnant women to get the influenza vaccine – not only for their benefit, but for the benefit of their unborn child.

For further information on vaccination and immunization schedules, visit the CDC website at the web address below:

www.cdc.gov/vaccines/recs/schedules/default.htm

Also, visit the CDC’s page on key facts regarding seasonal flu vaccine at the following web address:

www.cdc.gov/FLU/protect/keyfacts.htm

0 comments

Influenza vaccine: No efficacy in the elderly?

Consider the following scenario: You are a licensed pharmacist who is certified to administer vaccines and are currently spending time at a local community pharmacy immunizing patients against the influenza virus. An elderly gentleman walks up to you and says “I usually get the flu shot, but I’m not now – did you hear it doesn’t work?”

What is he talking about? How do you respond?

There have been a number of studies some recent, some a number of years old, that together call into question the benefit of the influenza vaccine in the elderly. Here is a straightforward review to help you educate your patients when you encounter the previously described situation. The information below will get some media attention and I expect the lay public to largely misunderstand what is being said.

What you need to know (a summary):

  1. A recent study published in the Lancet identifies a significant difference in the health, well being, and frailty of elderly patients that get the flu shot versus those that don’t. This difference equates to a bias when comparing the outcomes of these groups without controlling for these confounding factors. This has led several studies in the past to overestimate the effect of the flu shot in the elderly
  2. A study published in 2005 found that although the number of elderly receiving the flu shot more than tripled over the years 1980 to 2001, the death rate did not change
  3. In the mid ‘90s JAMA published findings that in the elderly 60-69 years old, the vaccine prevented influenza about 57% of the time compared to those ≥ 70 years old influenza was prevented only 23% of the time
  4. Plausibility At an annual vaccine conference, researchers recently presented findings that elderly patients require 4 times the amount of influenza antigens to elicit the same immune response as their younger aged peers

How should we interpret these findings?

  1. Immune senescence (waning immune system) leading to a less than ideal immune response to exposed antigens in the elderly is well known
  2. It is likely that previous studies have overestimated the efficacy of the influenza vaccine in the elderly, particularly those over 70. Before any further definitive recommendations can be made, further studies controlling for recently identified confounders needs to be conducted. An editorial identifying the appropriate methodology for this future study has already been published

Most importantly, what should we tell our patients?

  1. The Centers for Disease Control and Prevention (CDC) guidelines for those who should receive the flu shot will remain the same
  2. New studies show that the flu shot might not be as beneficial to the elderly as previously thought, but that doesn’t mean it doesn’t work
  3. The elderly should continue to receive the flu shot – some protection is better than none at all

0 comments

1918 Spanish Influenza Pandemic – Jury, but not Executioner

The 1918 Spanish Influenza Pandemic has been referred to as the “Great Flu”. Great in this context, however, denotes its ability to kill. It’s estimated that the overall death toll worldwide was 25 million people, of which 675,000 were from the United States. A recent study seeking the true cause of death associated with this pandemic was undertaken and lead by one of the most respected and well-known of NIH scientists, Dr. Anthony Fauci.


From the present day perspective, the year 1918 is a decade shy of a century ago, so how could these researchers possibly hope to answer this question? The answer: autopsy lung tissue specimens from 58 decedents infected during the 1918 Influenza pandemic. Jackpot!! The scientists of that time had the good sense to save these tissues for another time – now. The study is to be published in the Journal of Infectious Diseases and is available on-line ahead of print and accessible to you through the HSLS website (first author Morens, David M.) The authors found “The histologic spectrum observed in the cases corresponded to the characteristic pathology of bacterial pneumonia . . . . .” consistent with pneumococcal (another term for Streptococcus pneumoniae), streptococcal, and staphylococcal pneumonia. The clincher: according to the authors, bacteria were commonly seen in “massive numbers”.

Their conclusion, as suggested by this blog's title? It was pandemic influenza that caused severe illness, but it was the subsequent bacterial pneumonia that ultimately delivered the coup de grâce. Bacterial pneumonia after viral pneumonia is common today, too. The difference? 1918 was a time before vaccines, and especially, before antibiotics.

What are the implications for us now in the 21st century? It may be neurominidase inhibitors such as oseltamivir (Tamiflu) that will help to prevent the spread of the next pandemic, but antibiotics such as azithromycin will be used to make sure that a secondary bacterial infection won’t lead to the carnage seen early in the 20th century. Stockpiling of antibiotics for this purpose is already underway. We as pharmacists will be on the front lines of this battle if and when it comes.

1 comment

Students, Welcome Back!

I hope this blog is as informative, and thought provoking as it’s intended to be. Much of that depends on you - please feel free to comment and ask questions for the sake of discussion and learning. As we are on the cusp of another influenza season, I will create inaugural posts surrounding influenza. Stay posted . . . . . .

1 comment

Purpose


The infectious diseases blog is designed to complement the course goals of Pharmacotherapy of Infectious Diseases I and II. This is done by fostering the students’ critical thinking skills and infectious diseases knowledge by augmenting the existing coursework with emerging reports/data posted on the blog which directly impact the practice of pharmacy. The blog will provide students the opportunity to post comments and spur discussion between faculty and student, and among students themselves. Lastly, the blog is consistent with the School of Pharmacy’s Mission in using innovation in education and patient care.

0 comments